



Munich Re Group

Half-year financial report as at 30 June 2023

10 August 2023

Joachim Wenning (CEO)

Christoph Jurecka (CFO)



Half-year financial report as at 30 June 2023

Agenda







tampatra stock.adobe.com

01

Munich Re

After strong top- and bottom-line results in H1 2023, Munich Re well on track to achieving full-year targets



Increasing diversification of earnings profile provides tailwind for achieving Ambition 2025 targets

Strong underlying performance ...

1**Core P-C reinsurance**

Prolonged cycle supports profitable business

2**Global Specialty Insurance**

Becoming a powerful player in less cyclic specialty insurance

3**L&H reinsurance**

Strong earnings trajectory beyond expectations

4**ERGO**

Sustainably increasing contribution to Munich Re Group's earnings

... despite mixed macroeconomic environment

**Increased interest rates**

Clearly positive for Solvency II ratio and sustainable investment result

**Prevailing high inflation**

Impact well managed – consistently strong reserving position


1 Core P-C reinsurance: July renewals – Ongoing rate increases, focus on profitability




Price
change

Renewals 2019–2022

%



Volume
change



July renewals 2023¹

+5.1%

Material rate
increase in nat cat

–1.9%

Portfolio optimisation
and selective growth

Higher risk-adjusted pricing


- Conservative inflation and other loss-trend assumptions (e.g. nat cat modelling) fully reflected in risk- and mix-adjusted price change. Excluding the portfolio mix effect, the price change would be 3.0%
- Overall, markets behaving in a disciplined and risk-trend-conscious manner

Improved portfolio quality

- Continued improvement in terms and conditions in addition to higher attachment points and distinct pricing of covered perils, making portfolio more robust though not fully captured in numbers
- Prevailing market discipline allowed for ongoing tightening of wordings and targeted exclusions

1

Core P-C reinsurance: July renewals – Growth and risk/return optimisation well balanced



Property XL

Nat cat provides highly attractive margins

- Munich Re continues to have capacity within its overall risk appetite for cat business globally in a healthy pricing environment
- Strong growth with a material price improvement similar to those seen in January and April

Other lines of business

Higher inflation compensated

- Substantial nominal price increases protect margins of new business
- Reduction of proportional business with clients who fail to meet our requirements with respect to prices / terms and conditions

2

Global Specialty Insurance optimally positioned to deliver on targets while helping to decrease volatility

GUIDING PRINCIPLES



Efficient organisation

Capture economies of scale and expertise for GSI and Munich Re Group



Superior underwriting

Deliver underwriting/claims excellence to clients – advance data/analytics capabilities to drive better decision making, e.g. coordinated management of cat/cyber capacity



Focused innovation

Build for the future by investing in innovative technologies to enhance capabilities, processes and customer service, e.g. IoT sensor deployment


STRINGENCY



Comprehensive product, market and broker strategies

CONSISTENCY

Unified specialty insurance unit, operating as one company



AMBITION 2025



GSI to become a more powerful player in specialty insurance worldwide



Premium growth from €8bn (2022) to ~ €10bn

Based on IFRS 4




Combined ratio in the low 90s

Based on IFRS 4

3 Life and health reinsurance on a strong earnings trajectory beyond expectations

Total technical result¹

€m



	FinMoRe	Very positive business development beyond Ambition 2025 expectations driven by ongoing high demand
	Biometric risk-transfer	Better-than-expected new business growth, especially in the US
	Longevity	Leveraging the very pleasing development in line with strategy of cautious and gradual expansion in select countries
	IFRS 17	Crystallising business profitability through earlier earnings recognition

¹ Figures for 2020 and Ambition 2025 based on IFRS 4 technical result including fee income.


4

ERGO continues to deliver – Improving earnings contribution to Munich Re Group



ERGO steadily increasing earnings based
on strong underlying performance

Net profit
€m



¹ Based on IFRS4.



Improving profitability
relative to top peers



Above-average growth
in major markets



Top products and
customer experience



Becoming the digitally
leading insurer

4

Ambition 2025 – ERGO well on track to improving profitability relative to top peers



Above-average growth in major markets

- Superior underwriting in p-c, e.g. combined ratio in commercial far better than market
- Increase of market share in life new book
- Business expansion supported by leading position in German supplementary health
- Leveraging market-leading positions in Europe, e.g. Belgium and Poland
- Expansion in Asian markets, e.g. leveraging top 2 position¹ in India



Top products and customer experience

- Strong ratings for excellent product quality, e.g.
 - Biometric life products
 - Dental and long-term care products
 - Retail p-c portfolio
- Further enhancing the hybrid-customer model ...
- ... to provide consistent omni-channel products and services



Becoming the digitally leading insurer


- Supporting acceleration of cross-border synergies by leveraging global technology services
- Spearheading comprehensive set of digital technologies

¹ Among private p-c insurers.

Leveraging earnings power from our investment portfolio

Higher interest rates increasing sustainable investment result

Fixed-income portfolio



Levers to further improve investment performance



Seizing market opportunities within the tactical asset allocation, including active currency management



Earning liquidity premium through continuous expansion of alternative investments



Selecting best-in-class asset managers for specific asset classes and regions

ESG deeply embedded in our Ambition 2025 – Highlights

Insurance

Green Tech Solutions¹

Projects in the
“Green Tech” space
>900

Countries with
insured capacity
~80

Gigawatts
in total
>55



Net Promoter Score (NPS): 60 (2020/21: 56)

Reinsurance client survey 2022 (as of June 2022, bi-annually)

Munich Re **climate ambition unwavering** despite
discontinuation of our NZIA membership

Roll-out of strengthened
guidelines with regard to
biodiversity started

Member of the
**TNFD
Forum**

Own operations



Decarbonisation
achievement per employee⁴
approx. –22%
(compared to base year 2019)

Employees with
at least one training
>89%

Share of women
in management
38.5%

Electricity purchased
from renewable sources
90%

Number of nationalities
Munich Re Group
123

Investments



Rating coverage of
liquid asset classes
>95%

ESG-focus
investments²
€8.9bn

Emissions 2022³
–46%
(compared to base year 2019)

Active member of the **Net-Zero
Asset Owner Alliance**

Strengthened
guidelines with
regards to
biodiversity

Our commitment to success – Leading total shareholder return (TSR)

	Growth	Strong balance sheet – no constraints on deploying capital in hard market
	Profitability	Leveraging diversification and superior underwriting
	Capital repatriation	Shareholders participate via growing dividends and share buy-backs

TSR 1.1.2020 – 30.6.2023¹
%



¹ Source: Bloomberg. Peers: Allianz, Axa, Generali, Hannover Re, Scor, Swiss Re, Zurich.

Outlook 2023 – Well on track to achieve targets

Group

Insurance revenue (gross)
~ **€58bn**

Net result
~ **€4.0bn**

Return on investment
> **2.2%**

ERGO

Insurance revenue (gross)
~ **€19bn**

Net result
~ **€0.7bn**

Combined ratio
P-C Germany
~ **89%**

International
~ **90%**

Reinsurance


Insurance revenue (gross)
~ **€39bn**

Net result
~ **€3.3bn**

Combined ratio
Property-casualty
~ **86%**

Total technical result
Life and health
~ **€1.0bn**

Monstrous wave of new regulations makes Germany and Europe less attractive for global companies



New regulations lead to lasting high costs and jeopardize competitiveness

Examples ¹	Solvency II Pillar 3 (EU)	IFRS (Global)	ESRS (EU) - ISSB (Global)
Initial application	2016	2023	2024
Contents	Extensive data requirements and additional reporting duties towards supervisory authorities and the public	New accounting standards IFRS 9 and IFRS 17 for reporting to investors	Massive expansion of ESG reporting, with 12 (currently planned) European and 2 international standards
Costs			
Implementation	Low to mid three-digit- million euro range	Mid three-digit- million euro range	Low to mid three-digit- million euro range (expected)
Ongoing add-on costs due to new regulations	Annual mid double-digit million euro range	Annual mid double-digit million euro range	Not yet assessable; expected to be similar in magnitude to SII or IFRS
Effects on the Company	High degree of system and process complexity	Substantially higher demands on staff, systems and processes	Extensive requirements for data collection and data provision processes
Benefits for affected parties should be at the heart of the regulations		Reporting standards should be focused and internationally harmonised	Redundant requirements should be eliminated (e.g. HGB accounting for IFRS users)



02


Group finance

After strong H1 results well on track to achieve FY targets

Elevated result in H1 2022 due to lower unwinding effects (IFIE) and lower major losses


Net result

€m




Return on equity¹

%




Total technical result

€m




Net financial result

€m



Operating result

€m



RI net result Q2 (H1): €904m (€1,955m)

Sound operating performance in both segments, benign major losses in p-c, low RoI of 1.2%¹ due to disposal losses

Property-casualty: Combined ratio: 80.5% (83.5%) – major loss ratio: 9.3% (12.8%), reserve releases²: –5.0% (–5.0%) – net result: €578m (€1,338m)

Life and health: Total technical result: €325m (€644m) – net result: €326m (€617m)

July renewals: Risk-adjusted price change: +5.1%, premium change: –1.9%

ERGO net result Q2 (H1): €250m (€470m)

Strongly improved International business, ongoing sound CR in P-C Germany, low RoI in L&H Germany due to fair value changes

Life and Health Germany: Total technical result: €285m (€543m) – net result: €72m (€113m)

Property-casualty Germany: Combined ratio: 88.1% (84.7%) – net result: €62m (€229m)

International: Combined ratio: 88.1% (91.6%) – net result: €116m (€128m)

Capital position


Equity

€m

Equity 31.12.2022	27,245		Change in Q2
Net result	2,425		1,154
Changes			
Dividend	–1,583		–1,583
Share buy-backs	–496		–123
Unrealised gains/losses	507		–242
Exchange rates	–285		–4
Other ¹	–376		52
Equity 30.6.2023	27,436		–746

Capitalisation

€bn



Change in unrealised gains/losses

	Q2	H1
Investments	–€653m	€1,271m
Insurance contracts	€410m	–€764m

Return on equity

	Q2	H1
Reinsurance	14.9%	16.8%
ERGO	17.8%	17.3%


Solvency II ratio

273%

Investments


Investment portfolio¹

%



Government/Semi-government bonds ²	34 (34)	Alternative investments	15 (15)
Covered bonds/mortgage loans	15 (15)	Equities ³	5 (4)
Corporate bonds	14 (14)	Business-related participations	4 (4)
Emerging-market government bonds	4 (4)	Cash	7 (8)
ABS/MBS	3 (3)		

3-month reinvestment yield



Portfolio management in Q2

- Increase in equity exposure due to rising stock markets
- Increase in corporate bonds exposure ...
- ... and high interest rates benefit reinvestment yield

¹ Management view – not fully comparable with IFRS figures, e.g. including real estate in own use and cash. Fair values as at 30.6.2023 (31.12.2022).
² Developed markets. ³ Including derivatives: 3.4% (2.0%).

Investment result

€m	Q2 2023	Return ¹	H1 2023	Return ¹	H1 2022	Return ¹
Regular income	1,763	3.3%	3,364	3.1%	3,167	2.7%
Write-ups/write-downs	–11	0.0%	–39	0.0%	–1,805	–1.5%
Change in expected credit loss (ECL)	11	0.0%	–27	0.0%	0	0.0%
Disposal gains/losses	–396	–0.7%	–229	–0.2%	1,661	1.4%
Fair value change	–610	–1.1%	–535	–0.5%	–2,157	–1.8%
Other income/expenses	–162	–0.3%	–326	–0.3%	–292	–0.2%
Investment result	596	1.1%	2,208	2.0%	574	0.5%

	Q2 2023			H1 2023		
	Fixed income	Equities	Other	Fixed income	Equities	Other
Write-ups/write-downs	0	0	–11	0	0	–39
Disposal gains/losses	–399	0	3	–588	0	358
Fair-value change	–456	64	–218	–502	316	–350



03

ERGO

ERGO Life and Health Germany

Key messages



- Increase of total technical result in Q2 vs. Q1 driven by a higher contribution from PAA business (€51m)
- Net income in Q2 of €72m, H1 €113m – main contributor life back book, followed by health

Insurance revenue (gross)


€m



- Increase in insurance revenues driven by travel, short- and long-term health and life

Total technical result

€m




Strong Q2 total technical result driven by:

- CSM release in line with expectations
- Strong business growth and benign claims development in short-term health business (PAA)

Contractual service margin (CSM)¹

€m



- Increase of CSM in H1 driven by high operating changes and contribution from profitable new business partially compensated for by high CSM release

ERGO Property-casualty Germany

Key messages



- Exceptionally high total technical result in H1 driven by very low large losses and seasonally low acquisition costs
- Net result in H1 (€229m) significantly higher than H2 expectation; burden from acquisition costs in Q4

Insurance revenue (gross)


€m



- Good business development, mainly driven by motor, liability and others

Total technical result


€m



- Lower-than-expected man-made and nat cat major losses in Q2 and H1
- Low acquisition costs in Q1 to Q3 due to seasonality of new business; acquisition costs in Q4 significantly higher
- Higher-than-expected discount effect in CR (~3pp in H1) ...
- ... offset by prudent reflection of downside risks in basic loss ratio
- Q2 2023 discount effect of ~2.5pp
- Q2 2022 positively influenced by e.g. assumption changes

Combined ratio

%



Key messages



- Total technical result in Q2 supported by strong operating performance and benign large-loss development in P-C ...
- ... as well as CSM release at expected level, and release of claims reserves in life and health

Insurance revenue (gross)


€m



- Increase from strong business development, mainly driven by Belgium Health and Poland P-C and full consolidation of ERGO Thailand

Total technical result


€m



- CR in H1 of 91.6% (91.0%); strong CR in Q2 of 88.1% (93.3%) due to:
 - Favourable basic-loss development
 - Benign large losses
- In Q2, good development in life and health from CSM release and experience adjustment (claims reserve release in Belgium Health of ~€30m)

Contractual service margin (CSM)¹

€m



- Development in H1 mainly due to:
 - Profitable new business, ...
 - ... overcompensated for by operating changes and CSM release



04

Reinsurance

Life and health reinsurance

Key messages



- Strong total technical result above pro-rata guidance
- Pleasing new business development, especially in North America

Insurance revenue (gross)


€m



- Decline in Continental Europe and Asia, partly offset by growing revenue in North America and UK

Total technical result


€m



- Release of CSM and RA in line with expectations
- Pleasing underlying result from insurance-related financial instruments, however, negatively affected by FX effects of -€119m in H1 2023

Contractual service margin (CSM)¹

€m



- CSM from new contracts exceeds release through P&L
- Decline vs. year-end 2022 caused by a shift from CSM to RA, still representing future profits
- Negative FX impact in Q2 and H1

Property-casualty reinsurance

Key messages



- Strong revenue growth of 9.1% vs. H1 2022
- Combined ratio of 80.5% in Q2 supported by below-average major losses
- Normalised combined ratio of 86.2% in Q2 in line with guidance

Insurance revenue (gross)


€m



- Proportional business: New business and primary rate increases more than compensate for non-renewed shares
- XL business: Significant growth in nat cat at increased prices
- Global Specialty Insurance: Substantial growth across all units

Total technical result

€m




- Good CR in Q2/H1 2023, elevated vs. previous year due to higher major losses, lower release of loss component, and additional consideration of reserve uncertainty

- Current interest rates contributing to discounting effects in combined ratio of ~8pp in Q2

Combined ratio

%



- Higher-than-expected discount benefit used to cater for claims uncertainty in basic losses

This presentation contains forward-looking statements that are based on current assumptions and forecasts of the management of Munich Re. Known and unknown risks, uncertainties and other factors could lead to material differences between the forward-looking statements given here and the actual development, in particular of the results, financial situation and performance of our Group. Obvious fluctuations in the incidence of major losses in addition to the pronounced volatility of the capital markets and exchange rates – as well as the special features of IFRS accounting – make an accurate forecast of results impossible. The Group assumes no liability to update these forward-looking statements or to make them conform to future events or developments. Due to rounding, there may be minor deviations in summations and in the calculation of percentages in this presentation. Figures for FY 2022 are based on IFRS 17 and IAS 39 including overlay approach.